scholarly journals TO STUDY AYURVEDIC MANAGEMENT OF ALOPECIA AREATA (INDRALUPTA)

Author(s):  
Sayali Sudesh Vora

Alopecia areata is a T cell driven auto immune disorder producing non scarring alopecia. The cause of this disease is unknown. It is also known as spot baldness.It causes hair loss of scalp, face and sometimes other areas of body. [1]              The lifetime incidence of alopecia areata is 0.1% – 0.2% of the population. More than half of affected patients are younger than 20 years. There is no predictable treatment in modern medicine. High and super potency corticosteroids are used orally, topically or intradermal injections. But mode of treatment is impractical in children             According to Ayurveda, Indralupta is one of the type of khalitya .Ayurvedic texts in the context of khalitya explained is primarily predominant tridoshajanya vyadh

2018 ◽  
Vol 5 (1) ◽  
pp. e000291 ◽  
Author(s):  
Josef Symon Salgado Concha ◽  
Victoria P Werth

Several patterns of hair loss can occur in lupus erythematosus (LE). Alopecias which show histological characteristics of LE are LE-specific, and include discoid LE (DLE), diffuse or patchy hair loss in acute LE, subacute cutaneous LE, and rarely tumid LE. Lupus hair in SLE is a poorly characterised entity and may be a form of telogen effluvium. Alopecia areata can coexist with LE and may mimic DLE. Non-lupus alopecias such as telogen effluvium and anagen effluvium have a myriad of causes which include disease flares, drugs and stress in the setting of LE. The latest validated Systemic Lupus International Collaborating Clinics classification criteria for SLE includes non-scarring alopecia as a criterion; therefore, recognising the aetiology of hair loss in the setting of LE is crucial in classifying a patient to have systemic disease.


2021 ◽  
pp. 1-5
Author(s):  
Chloe J. Walker ◽  
Kelly E. Flanagan ◽  
James T. Pathoulas ◽  
Isabel Pupo Wiss ◽  
Maryanne M. Senna

<b><i>Introduction:</i></b> Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. <b><i>Case Presentation:</i></b> Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. <b><i>Discussion:</i></b> Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.


2021 ◽  
Vol 141 (5) ◽  
pp. S78
Author(s):  
K.E. Flanagan ◽  
J.T. Pathoulas ◽  
C.J. Walker ◽  
I. M. Pupo Wiss ◽  
M.M. Senna

2021 ◽  
Vol 7 (4) ◽  
pp. 311-314
Author(s):  
Leticia Arsie Contin ◽  
Leopoldo Duailibe Nogueira Santos ◽  
Ivan José Netto Pereira ◽  
Vanessa Barreto Rocha

<b><i>Introduction:</i></b> Many procedures are performed on the scalp, such as excision of pilar and sebaceous cysts, melanocytic nevi, and reduction surgery for scarring alopecia, among others. In hair transplants, telogen effluvium is often reported 3 months after surgery; however, hair loss usually happens much earlier, around second week after the procedure, not compatible with the time required for hair to enter telogen and exogenous phases in normal conditions. <b><i>Case Reports:</i></b> We report 3 cases of anagen hair loss 4 weeks after surgeries, with perilesional trichoscopy suggesting anagen effluvium, with typical signs such as black dots and exclamation hairs. <b><i>Discussion:</i></b> There are only a few reports about hair loss around operated areas. The cause of this postoperative anagen effluvium is probably a transient ischemia. <b><i>Conclusion:</i></b> The practical importance of this phenomenon is to properly orient patients because most of the hair will be lost, since 85% of them are anagens, and also will have spontaneous recovery in the next 3 months.


2020 ◽  
Vol 21 (21) ◽  
pp. 8390
Author(s):  
Antonio Martinez-Lopez ◽  
Trinidad Montero-Vilchez ◽  
Álvaro Sierra-Sánchez ◽  
Alejandro Molina-Leyva ◽  
Salvador Arias-Santiago

Alopecia is a challenging condition for both physicians and patients. Several topical, intralesional, oral, and surgical treatments have been developed in recent decades, but some of those therapies only provide partial improvement. Advanced medical therapies are medical products based on genes, cells, and/or tissue engineering products that have properties in regenerating, repairing, or replacing human tissue. In recent years, numerous applications have been described for advanced medical therapies. With this background, those therapies may have a role in the treatment of various types of alopecia such as alopecia areata and androgenic alopecia. The aim of this review is to provide dermatologists an overview of the different advanced medical therapies that have been applied in the treatment of alopecia, by reviewing clinical and basic research studies as well as ongoing clinical trials.


2013 ◽  
Vol 40 (5) ◽  
pp. 399-401 ◽  
Author(s):  
Taisuke Ito ◽  
Shinichiro Shimada ◽  
Tatsuyoshi Mori ◽  
Yoshiki Tokura

Author(s):  
Natalie V. J. Aldhouse ◽  
Helen Kitchen ◽  
Sarah Knight ◽  
Jake Macey ◽  
Fabio P. Nunes ◽  
...  

Abstract Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes the psychosocial burden of AA. Methods Participants diagnosed with AA who had experienced ≥50% scalp hair loss according to the Severity of Alopecia Tool (SALT) were identified by clinicians. A semi-structured interview guide, developed with expert clinician input, included open-ended questions to explore patients’ experiences of living with AA. Data were thematically analyzed to identify concepts and relationships. Results Participants (n = 45, 58% female, mean age 33.3 years [range 15–72], mean SALT 67.2 [range 0–100]) described the AA diagnosis as “devastating”. Both males and females reported emotional and psychological impacts of AA including feeling sad/depressed (n = 21), embarrassed/ashamed (n = 10) and angry/frustrated (n = 3). Patients felt helpless (n = 5) due to the unpredictability of disease recurrence, and anxious (n = 19) about judgement from others. Many patients avoided social situations (n = 18), which impaired relationships and increased isolation. Coping strategies included concealment of hair loss through wigs or make-up, although fear of the displacement of these coverings also caused anxiety and the avoidance of activities that could result in scalp exposure (n = 22). Some patients became more accepting of AA over time, which lessened the emotional impact, though efficacious treatment was still desired. A conceptual framework was developed, and a conceptual model was created to depict the relationship between the physical signs/symptoms and the associated psychosocial effects of AA. Conclusion AA impairs patients’ emotional and psychological wellbeing, relationships and lifestyles. Greater disease awareness and effective treatments are needed.


JCI Insight ◽  
2018 ◽  
Vol 3 (19) ◽  
Author(s):  
Annemieke de Jong ◽  
Ali Jabbari ◽  
Zhenpeng Dai ◽  
Luzhou Xing ◽  
Dustin Lee ◽  
...  

2021 ◽  
pp. 1-5
Author(s):  
Mehdi Gheisari ◽  
Khatere Zahedi ◽  
Zohreh Tehranchinia ◽  
Hamideh Moravvej ◽  
Fahimeh Abdollahimajd ◽  
...  

<b><i>Introduction:</i></b> The pandemic of COVID-19 has several implications for patients with chronic stress-sensitive diseases such as alopecia areata (AA). On the other hand, the vulnerability of AA patients using immunosuppressives to a more severe infection is in the shadow of ambiguity. This teledermatology study aimed to evaluate the course and outcome of AA in patients during this challenging period. <b><i>Methods:</i></b> Patients with AA who had previously received systemic therapy included in this study. Information about demographic data, AA history, characteristics, and treatments, hair loss progression, Corona Disease Anxiety Scale (CDAS), adherence to protective measures against the COVID-19, possible infection, and its features obtained via a telephone call. <b><i>Results:</i></b> A total of 57 patients participated. The majority (84.2%) of the participants had mild anxiety assessed by CDAS. Two patients (3.5%) had got infected with COVID-19. Twenty-one (36.8%) participants experienced hair loss progression. Hair loss progression correlated with drug dose reduction (OR: 46.09, 95% CI 5.48–387.14, <i>p</i> &#x3c; 0.001) although it did not influence by the level of anxiety evaluated by the CDAS (<i>p</i> &#x3e; 0.05). <b><i>Conclusion:</i></b> The anxiety perceived by severe AA patients about COVID-19 is mild; however, many experience hair loss progressions owing to their drug dose reduction.


Sign in / Sign up

Export Citation Format

Share Document